BioNTech (BNTX)
(Delayed Data from NSDQ)
$111.77 USD
-2.70 (-2.36%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $111.72 -0.05 (-0.04%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.77 USD
-2.70 (-2.36%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $111.72 -0.05 (-0.04%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth D Momentum C VGM
Zacks News
How Will Pfizer's (PFE) Key Drugs Perform in Q2 Earnings?
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q2.
Pfizer (PFE) to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q2.
Should Value Investors Buy BioNTech (BNTX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How Much Upside is Left in BioNTech SE Sponsored ADR (BNTX)? Wall Street Analysts Think 40.69%
by Zacks Equity Research
The mean of analysts' price targets for BioNTech SE Sponsored ADR (BNTX) points to a 40.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug
by Zacks Equity Research
Based on feedback from the FDA, Iovance's (IOVA) ongoing mid-stage study on LN-145 in NSCLC could support approval under the accelerated pathway. IOVA also reports encouraging preliminary data.
New Strong Buy Stocks for July 11th
by Zacks Equity Research
BLBD, BNTX, EC, TIMB and HIVE have been added to the Zacks Rank #1 (Strong Buy) List on July 11, 2023.
Novavax's (NVAX) COVID Jab Gets Full Approval in Europe
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe.
Moderna (MRNA) Submits Filing in EU for Updated COVID-19 Jab
by Zacks Equity Research
Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. If the filing is approved in the EU, the vaccine will be made available for the fall season.
Moderna (MRNA) Seeks FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. The company expects the vaccine to be available for the fall season, provided the FDA authorizes the same.
Implied Volatility Surging for BioNTech (BNTX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.
FDA Panel Endorses Updating COVID Jab to Target XBB Strain
by Zacks Equity Research
An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.
BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody
by Zacks Equity Research
BioNTech (BNTX) announces positive initial data evaluating BNT316/ONC-392 to treat metastatic non-small cell lung cancer.
EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.
Are Options Traders Betting on a Big Move in BioNTech (BNTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.
Will Pfizer (PFE) Beat Expectations This Earnings Season?
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q1.
FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations
by Sundeep Ganoria
To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.
BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $124.57, marking a +1.63% move from the previous day.
Wynn Resorts and BioNTech have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Wynn Resorts and BioNTech have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: BioNTech (BNTX)
by Andrew Rocco
BNTX is ranked a lowly 5 for a reason. Earnings have peaked, COVID hysteria has subsided, and the technical picture is lagging.
Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $132.08, marking a +1.88% move from the previous day.
Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.
Deciphera Pharmaceuticals, Inc. (DCPH) Soars 10.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $129.77, moving +1.82% from the previous trading session.